|
Active substance |
dupilumab |
|
Holder |
Sanofi Belgium |
|
Status |
Running |
|
Indication |
add-on therapy with intranasal corticosteroids for treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients who have participated and exited the phase 4 clinical study EVEREST (LPS16747). |
|
Public documents |
|
|
Last update |
22/12/2023 |
Dupixent
Last updated on 07/11/2024